The most studied molecular targets in breast cancer drug discovery included epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor‐2 (VEGFR‐2), cyclin‐dependent kinases (CDKs), tubulin, and hormone receptors (ERα and ERβ) (Table 4). The gene discussed is EGFR; the disease is breast carcinoma.